FDA accepts New Drug Application for Eyenovia pupil dilation tech

Eyenovia (NSDQ:EYEN) announced today that the FDA accepted its New Drug Aplication for its MydCombi pupil dilation agent.

MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0